Literature DB >> 6304800

High-dose naloxone affects task performance in normal subjects.

R M Cohen, M R Cohen, H Weingartner, D Pickar, D L Murphy.   

Abstract

Increasing intravenous doses of naloxone (0.3 mg/kg, 1 mg/kg, and 2 mg/kg) were administered to normal subjects. Naloxone at 2 mg/kg, but not at lower doses, impaired aspects of memory as measured by a verbal learning task which assessed the direct free recall and recognition of presented versus non-presented words of a single category (effortful processing) and the monitoring of the frequency of such presentations (automatic processing). At the same time "working" memory was left unaffected. The results suggest a role for the opioid system in some memory processes in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6304800     DOI: 10.1016/0165-1781(83)90100-2

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Authors:  Samuel R Chamberlain; Karin Mogg; Brendan P Bradley; Annelize Koch; Chris M Dodds; Wenli X Tao; Kay Maltby; Bhopinder Sarai; Antonella Napolitano; Duncan B Richards; Edward T Bullmore; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-03       Impact factor: 4.530

2.  Effect of naltrexone on senile dementia of the Alzheimer type.

Authors:  B T Hyman; P J Eslinger; A R Damasio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

3.  Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls.

Authors:  T Sunderland; H Weingartner; R M Cohen; P N Tariot; P A Newhouse; K E Thompson; B A Lawlor; E A Mueller
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Cognitive effects of L-deprenyl in Alzheimer's disease.

Authors:  P N Tariot; T Sunderland; H Weingartner; D L Murphy; J A Welkowitz; K Thompson; R M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

6.  Naloxone's effect on cognitive functioning in drug-free and diazepam-treated normal humans.

Authors:  O M Wolkowitz; J R Tinklenberg
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.

Authors:  Vanessa Minervini; Alex Disney; Stephen M Husbands; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2020-08-09       Impact factor: 4.530

8.  Scopolamine challenges in Alzheimer's disease.

Authors:  T Sunderland; P Tariot; D L Murphy; H Weingartner; E A Mueller; R M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Effect of forced treadmill exercise and blocking of opioid receptors with naloxone on memory in male rats.

Authors:  Atefeh Asadi Rizi; Parham Reisi; Nooshin Naghsh
Journal:  Adv Biomed Res       Date:  2016-02-08

10.  Naloxone modulates visual judgments of similarity but not dissimilarity.

Authors:  Peter Krummenacher; Elvan Kut; Gerd Folkers; Peter Brugger
Journal:  Cogn Affect Behav Neurosci       Date:  2013-09       Impact factor: 3.526

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.